Epigenetic Modulation by Apabetalone Counters Cytokine-Driven Acute Phase Response In Vitro, in Mice and in Patients with Cardiovascular Disease

Figure 1

Apabetalone alters basal expression of genes within the APR pathway under noninflammatory conditions in human hepatocytes. (a) rtPCR shows that apabetalone (30 μM) treatment decreases the expression of APR genes (72 h). Gene expression is normalized to vehicle (DMSO) treated cells. (b) Apabetalone (30 μM) decreases APR protein secretion after 72 h of treatment. Protein secretion in the final 24 h of treatment is measured by ELISA and is expressed as nanograms per milliliter of tissue culture media. Representative data is shown. (c) APR gene expression in humanized liver of chimeric mice. Mice received 150 mg b.i.d. apabetalone or vehicle treatment for 1 to 3 days. Mean data normalized to naïve is shown. Statistical significance was determined through -test comparison of vehicle and apabetalone treatment, where , , , and ns means no significant difference.

(a)

(b)

(c)